Cognition Therapeutics (CGTX) News Today $0.45 0.00 (-0.31%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.46 +0.02 (+3.63%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Brokerages Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) Target Price at $7.13May 1, 2025 | americanbankingnews.comCognition Therapeutics presents results at AD/PD 2025 on CT1812April 2, 2025 | markets.businessinsider.comCognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease ProcessesApril 1, 2025 | markets.businessinsider.comCognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease ProcessesApril 1, 2025 | globenewswire.comCognition to Reveal Biomarker Findings Next WeekMarch 25, 2025 | baystreet.caCognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025March 25, 2025 | globenewswire.comCognition Therapeutics price target lowered to $5 from $6 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comEarnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net lossMarch 22, 2025 | uk.investing.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comCognition Therapeutics price target lowered to $8 from $11 at ChardanMarch 22, 2025 | markets.businessinsider.comCognition Therapeutics Earnings Call: Progress Amid ChallengesMarch 21, 2025 | tipranks.comCognition Therapeutics Advances Alzheimer’s and DLB TrialsMarch 21, 2025 | tipranks.comCognition Therapeutics reports FY24 EPS (86c), consensus (74c)March 20, 2025 | markets.businessinsider.comCognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comCognition Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comCognition Therapeutics shifts to Nasdaq Capital MarketMarch 14, 2025 | investing.comCognition Therapeutics to Report Fourth Quarter and Full Year 2024 ResultsMarch 13, 2025 | globenewswire.comCognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange ListingMarch 12, 2025 | globenewswire.comCognition Therapeutics to Present at Life Sciences Virtual Investor ConferenceMarch 10, 2025 | globenewswire.comCognition Therapeutics, Inc.: Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMDFebruary 27, 2025 | finanznachrichten.deCognition Therapeutics publishes research on zervimesine in dry AMDFebruary 27, 2025 | markets.businessinsider.comCognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMDFebruary 27, 2025 | globenewswire.comCognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic AtrophyFebruary 26, 2025 | markets.businessinsider.comCognition Therapeutics passes pre-defined futility analysis of Phase 2 studyFebruary 26, 2025 | markets.businessinsider.comCognition VP co-hosting workshop at Neuroimmunology Drug Development SummitFebruary 25, 2025 | markets.businessinsider.comCognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development SummitFebruary 25, 2025 | markets.businessinsider.comCognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development SummitFebruary 25, 2025 | globenewswire.comCognition announces publication of zervimesine manufacturing processFebruary 20, 2025 | markets.businessinsider.comCognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)February 20, 2025 | markets.businessinsider.comCognition Therapeutics price target raised to $2 from $1.50 at B. RileyFebruary 6, 2025 | markets.businessinsider.comCognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDCJanuary 30, 2025 | markets.businessinsider.comCognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDCJanuary 30, 2025 | globenewswire.comCognition Therapeutics CEO Participating in Longwood and Sachs ConferencesJanuary 8, 2025 | globenewswire.comB. Riley Securities Upgrades Cognition Therapeutics (CGTX)December 21, 2024 | msn.comCognition Therapeutics, Inc.: Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy BodiesDecember 19, 2024 | finanznachrichten.deThis Biotech Is Already Off To The Races Before The Opening BellDecember 18, 2024 | theglobeandmail.comCognition Therapeutics (NASDAQ:CGTX) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comCognition Therapeutics announces results in Phase 2 study of CT1812December 18, 2024 | markets.businessinsider.comWhy Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?December 18, 2024 | benzinga.comCognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy BodiesDecember 18, 2024 | globenewswire.comWe're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn RateDecember 13, 2024 | finance.yahoo.comPositive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition TherapeuticsNovember 28, 2024 | markets.businessinsider.comCognition announces all participants completed final visit in SHIMMER studyNovember 26, 2024 | markets.businessinsider.comCognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy BodiesNovember 26, 2024 | globenewswire.comCognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysisNovember 25, 2024 | markets.businessinsider.comCognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s PopulationNovember 25, 2024 | markets.businessinsider.comCognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's PopulationNovember 25, 2024 | globenewswire.comCognition Therapeutics Reports Promising Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateNovember 14, 2024 | finanznachrichten.deCognition Therapeutics sees cash runway into 2Q25November 14, 2024 | markets.businessinsider.com Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CGTX Media Mentions By Week CGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼0.000.73▲Average Medical News Sentiment CGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼12▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Coya Therapeutics News Today BioHarvest Sciences News Today Vaxart News Today Zentalis Pharmaceuticals News Today Sagimet Biosciences News Today Genelux News Today Zura Bio News Today Atossa Therapeutics News Today Senti Biosciences News Today OptiNose News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGTX Stock Free CGTX Stock Alerts